{"generic":"Fulvestrant","drugs":["Faslodex","Fulvestrant"],"mono":{"0":{"id":"jv91s0","title":"Generic Names","mono":"Fulvestrant"},"1":{"id":"jv91s1","title":"Dosing and Indications","sub":[{"id":"jv91s1b4","title":"Adult Dosing","mono":"<b>Metastatic breast cancer, Hormone receptor-positive, postmenopausal with disease progression following antiestrogen therapy:<\/b> 500 mg IM on days 1, 15, 29, and once monthly thereafter "},{"id":"jv91s1b5","title":"Pediatric Dosing","mono":"efficacy not established in girls with McCune-Albright syndrome and progressive precocious puberty "},{"id":"jv91s1b6","title":"Dose Adjustments","mono":"<b>hepatic, moderate (Child-Pugh class B):<\/b> 250 mg IM on days 1, 15, 29, and once monthly thereafter; administer slowly (1 to 2 minutes per injection) into the buttock as one 5-mL injection "},{"id":"jv91s1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Metastatic breast cancer, Hormone receptor-positive, postmenopausal with disease progression following antiestrogen therapy<br\/>"}]},"3":{"id":"jv91s3","title":"Contraindications\/Warnings","sub":[{"id":"jv91s3b9","title":"Contraindications","mono":"<ul><li>hypersensitivity to fulvestrant  or to any of its components<\/li><li>suspected or known pregnancy<\/li><\/ul>"},{"id":"jv91s3b10","title":"Precautions","mono":"hepatic impairment<br\/>"},{"id":"jv91s3b11","title":"Pregnancy Category","mono":"D (FDA)<br\/>"},{"id":"jv91s3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"jv91s5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Vasodilatation (17.7%)<\/li><li><b>Dermatologic:<\/b>Injection site pain (9.1% to 11.6%), Injection site reaction (7% to 27%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (11.8%), Constipation (3.5% to 12.5%), Diarrhea (12.3%), Nausea (9.7% to 26%), Vomiting (5.6% to 13%)<\/li><li><b>Hepatic:<\/b>Liver enzymes abnormal, Raised (greater than 15%)<\/li><li><b>Musculoskeletal:<\/b>Backache (7.5% to 14.4%), Bone pain (7.5% to 15.8%)<\/li><li><b>Neurologic:<\/b>Asthenia (5.8% to 22.7%), Headache (6.7% to 15.4%)<\/li><li><b>Reproductive:<\/b>Menopausal flushing (5.9% to 6.6%)<\/li><li><b>Respiratory:<\/b>Cough (5.3%), Dyspnea (4.4% to 14.9%), Increasing frequency of cough (10.4%), Pharyngitis (16.1%)<\/li><li><b>Other:<\/b>Pain (18.9%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Hematologic:<\/b>Thromboembolic disorder (less than 1%)<\/li><li><b>Hepatic:<\/b>Hepatitis (less than 1%), Liver failure (less than 1%)<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction (less than 1%)<\/li><li><b>Other:<\/b>Angioedema (less than 1%)<\/li><\/ul>"},"6":{"id":"jv91s6","title":"Drug Name Info","sub":{"0":{"id":"jv91s6b17","title":"US Trade Names","mono":"Faslodex<br\/>"},"2":{"id":"jv91s6b19","title":"Class","mono":"Antiestrogen<br\/>"},"3":{"id":"jv91s6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jv91s6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jv91s7","title":"Mechanism Of Action","mono":"<ul><li>Systemic: Fulvestrant is an estrogen receptor antagonist that binds to the estrogen receptor in a competitive manner with affinity comparable to estradiol. Fulvestrant down regulates the estrogen receptors (ER) protein in human breast cancer cells.<\/li><li>Clinical studies demonstrate down regulation of ER increases with increasing dose. This down regulation is associated with a dose-related decrease in the expression of the progesterone receptor, an estrogen-related protein. These effects on the ER pathway were also associated with a decrease in Ki67 labeling index, a marker of cell proliferation.<\/li><\/ul>"},"8":{"id":"jv91s8","title":"Pharmacokinetics","sub":{"1":{"id":"jv91s8b24","title":"Distribution","mono":"Systemic: Vd: 3 to 5 L\/kg <br\/>"},"2":{"id":"jv91s8b25","title":"Metabolism","mono":"Systemic: Hepatic: via CYP3A4 pathway <br\/>"},"3":{"id":"jv91s8b26","title":"Excretion","mono":"Systemic: Fecal: 90%; Renal: &lt;1%<br\/>"},"4":{"id":"jv91s8b27","title":"Elimination Half Life","mono":"Systemic: 40 d <br\/>"}}},"9":{"id":"jv91s9","title":"Administration","mono":"<b>Intramuscular<\/b><br\/><ul><li>administer the recommended 500-mg dose slowly (1 to 2 minutes per injection) into the buttocks as two 5-mL injections (one in each buttock)<\/li><li>for the 2 x 5 mL package, use both syringes to receive the 500-mg dose<\/li><\/ul>"},"10":{"id":"jv91s10","title":"Monitoring","mono":"evidence of tumor response may indicate efficacy<br\/>"},"11":{"id":"jv91s11","title":"How Supplied","mono":"<b>Faslodex<\/b><br\/>Intramuscular Solution: 50 MG\/ML<br\/>"},"12":{"id":"jv91s12","title":"Toxicology","sub":[{"id":"jv91s12b31","title":"Clinical Effects","mono":"<b>FULVESTRANT<\/b><br\/>OVERDOSE: Data are limited. No adverse effects were reported when intravenous fulvestrant was administered to achieve peak plasma concentrations 10-15 times those seen at therapeutic intramuscular doses. Mild (grade 1) side effects including headache, hot flushes, and gastrointestinal disturbances were seen in premenopausal women receiving one 750 mg fulvestrant intramuscular injection. ADVERSE EFFECTS: The most common adverse reactions following administration of fulvestrant include nausea, vomiting, diarrhea, constipation, headache, back pain, vasodilation (hot flushes), and injection site reactions.<br\/>"},{"id":"jv91s12b32","title":"Treatment","mono":"<b>FULVESTRANT<\/b><br\/><ul><li>Decontamination: Decontamination is not indicated; fulvestrant is administered parenterally.<\/li><li>Support: In cases of fulvestrant overdose, treatment is symptomatic and supportive.<\/li><li>Monitoring of patient: Monitor fluid and electrolyte status in patients with severe vomiting and\/or diarrhea. Monitor pulse and blood pressure in symptomatic patients.<\/li><li>Enhanced elimination procedure: Due to the high protein binding of fulvestrant, hemodialysis is not expected to be an effective method of enhanced elimination.<\/li><\/ul>"},{"id":"jv91s12b33","title":"Range of Toxicity","mono":"<b>FULVESTRANT<\/b><br\/> TOXICITY: A specific toxic dose has not been established. Mild (grade 1) side effects, such as headache, hot flushes, and gastrointestinal disturbances, were seen in one clinical trial of premenopausal women with a single intramuscular injection of fulvestrant 750 mg (three times the recommended dose). THERAPEUTIC DOSE: The recommended dose of fulvestrant is 250 mg intramuscular injection once monthly.<br\/>"}]},"13":{"id":"jv91s13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause abdominal pain, constipation, diarrhea, nausea, vomiting, back pain, headache, or pharyngitis.<\/li><li>Instruct patient to report any vaginal bleeding, especially at initiation of therapy.<\/li><li>Advise patient to call a healthcare professional if a dose is missed, as drug should be given on a regular schedule.<\/li><\/ul>"}}}